Lantheus (NASDAQ:LNTH) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Lantheus (NASDAQ:LNTH) in a research report report published on Tuesday morning,Benzinga reports. JMP Securities currently has a $112.00 price target on the medical equipment provider’s stock.

A number of other research analysts also recently weighed in on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Price Performance

LNTH opened at $92.62 on Tuesday. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market cap of $6.44 billion, a price-to-earnings ratio of 15.41 and a beta of 0.46. The firm has a 50 day simple moving average of $89.53 and a 200 day simple moving average of $99.87.

Institutional Trading of Lantheus

A number of large investors have recently bought and sold shares of LNTH. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares during the period. Groupama Asset Managment acquired a new position in Lantheus in the 3rd quarter worth $439,000. Point72 Asset Management L.P. bought a new position in Lantheus during the 2nd quarter worth about $26,794,000. Janus Henderson Group PLC raised its stake in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after purchasing an additional 257,022 shares during the period. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus in the third quarter valued at about $25,955,000. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.